1. Metric Overview

The Molecular Geometry Index Score (MGIS) is the SEF metric used to quantify the structural, spatial, and pharmacokinetic alignment of a therapeutic molecule or multi-component therapeutic system relative to its intended biologic target environment.

MGIS evaluates whether a therapeutic candidate exhibits:

• favorable ligand–target geometric fit
• coherent spatial orientation
• stable temporal-decay behavior
• pharmacokinetic compatibility across delivery and exposure phases

Within the SCF principle map, MGIS directly operationalizes Pharmacokinetic Optimization.

Where TSSM evaluates therapeutic strength, HSV-F² evaluates energetic coherence, and SV-EQ evaluates target specificity, MGIS evaluates whether the therapeutic system is physically and kinetically shaped to arrive, engage, and persist in the correct biologic context.

2. Conceptual Rationale

A therapeutic may be potent, specific, and metabolically tolerable, yet still fail if its structural and kinetic properties are misaligned with the target site. In pharmacology, this misalignment may appear as:

• weak docking geometry
• unstable receptor residence
• poor tissue penetration
• premature degradation
• incoherent release behavior

SCF therefore defines pharmacokinetic optimization not only as ADME performance, but as geometry-in-time compatibility.

MGIS integrates three core dimensions:

3. Mathematical Formulation

The base MGIS equation is defined as:

$MGIS = G \times K \times D$

Where:

A weighted form may be used for therapeutic-area calibration:

$MGIS = G^{\alpha} \times K^{\beta} \times D^{\gamma}$

Typical starting values:

$\alpha = 1,\quad \beta = 1,\quad \gamma = 1$

4. Component Definitions

4.1 Geometric Fit Coefficient (G)

This term measures the structural complementarity between the therapeutic agent and its intended biologic target.

A normalized formulation is:

$G = \frac{A_{bind} \times C_{shape}}{\Delta E_{dock} + \varepsilon}$

Where:

Higher G indicates stronger and more coherent structural engagement.

In practice, $C_{shape}$ may be derived from molecular overlay, RMSD-normalized fit, pocket occupancy, or pharmacophore alignment.

4.2 Kinetic Stability Coefficient (K)

This term measures the time coherence of therapeutic engagement relative to decay and clearance.

A practical formulation is:

$K = \frac{t_{res}}{t_{deg} + t_{clr}}$

Where:

Higher K values indicate that target engagement is maintained relative to system loss processes.

Alternative forms may incorporate dissociation rate constants:

$K = \frac{1/k_{off}}{t_{deg} + t_{clr}}$

where $k_{off}$ is the ligand dissociation rate.

4.3 Delivery/Spatial Alignment Coefficient (D)

This term measures how efficiently the therapeutic system reaches and distributes within the intended biologic compartment.

A normalized expression is:

$D = \frac{C_{target}}{C_{systemic} + \sigma_{dist}}$

Where:

Higher D indicates better tissue localization and less diffuse exposure.

This component captures delivery efficiency, tissue selectivity, and compartmental coherence.

5. Expanded MGIS Equation

Substituting components:

$MGIS = \left( \frac{A_{bind} \times C_{shape}}{\Delta E_{dock} + \varepsilon} \right)^{\alpha} \times \left( \frac{t_{res}}{t_{deg} + t_{clr}} \right)^{\beta} \times \left( \frac{C_{target}}{C_{systemic} + \sigma_{dist}} \right)^{\gamma}$

This equation integrates structural fit, temporal stability, and tissue-delivery alignment into a single pharmacokinetic-geometry score.

6. Biological Interpretation

High MGIS values suggest the therapeutic candidate is structurally suited to engage the target and kinetically suited to remain useful in the biologic environment.

7. Experimental Measurement

MGIS can be estimated from a combination of in silico, in vitro, and in vivo data.

Geometric Fit Inputs

Measured using:

• molecular docking
• molecular dynamics simulation
• pharmacophore overlay analysis
• pocket occupancy mapping
• ligand RMSD / shape complementarity scoring

Kinetic Stability Inputs

Measured using:

• surface plasmon resonance (SPR)
• biolayer interferometry
• receptor residence time studies
• microsomal stability assays
• plasma degradation assays

Delivery/Spatial Alignment Inputs

Measured using:

• biodistribution studies
• imaging-based tissue concentration profiling
• PK compartment modeling
• organoid penetration assays
• tissue-to-plasma concentration ratios

These measurement domains align with the SEF concept that pharmacokinetic optimization depends on geometry, timing, and compartmental precision.

8. Example Calculation

Assume the following normalized values:

First, geometric fit:

$G = \frac{0.80 \times 0.90}{0.60 + 0.05}$

$G = \frac{0.72}{0.65} \approx 1.11$

Next, kinetic stability:

$K = \frac{8}{2+2} = \frac{8}{4} = 2.0$

Then, delivery alignment:

$D = \frac{1.20}{0.60 + 0.20} = \frac{1.20}{0.80} = 1.5$

Thus:

$MGIS = 1.11 \times 2.0 \times 1.5$

$MGIS \approx 3.33$

Interpretation: highly optimized geometry–kinetic compatibility.

9. Role in SCF Drug Design

Within the SCF development workflow, MGIS is used to:

• rank scaffold designs by structural fit
• optimize delivery systems and tissue targeting
• compare formulations with similar potency but different PK behavior
• prioritize candidates with high residence time and low diffuse exposure

MGIS is especially valuable in:

• oncology targeted therapeutics
• antiviral tissue-selective agents
• mucosal or organ-specific delivery programs
• nanoparticle and prodrug engineering

10. Limitations

Future refinement may incorporate full molecular dynamics ensembles, nonlinear compartment models, and target microenvironment weighting.

Summary

The Molecular Geometry Index Score (MGIS) quantifies whether a therapeutic system is structurally and kinetically configured to achieve effective target engagement in the correct biologic compartment. By integrating geometric fit, kinetic stability, and delivery alignment, MGIS operationalizes the SCF principle of Pharmacokinetic Optimization.